...ex and expensive therapeutic protocols. Clinicians will be able to prescribe personalized treatments and to prolong patients’ lives, thereby reducing medical expenses.The new test is based on the ICELLTIS breakthrough 3D multicellular tumor spheroids, which are specific to RCC. For the first time, these spheroids are composed of the patient’s own tumor and immune cells, which are key determinants ...